Evidence map›Paper›PMID 34517865›Full record

ArticleJournal of biomedical science2021

Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine.

Ssu-Hsueh Tseng, Li Liu, Shiwen Peng, Jinhwi Kim, Louise Ferrall, Chien-Fu Hung, T -C Wu

Open access · diamondAbstract read
In one paragraph

Article in Journal of biomedical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Trends in immunotherapy for oral squamous cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2025
    Review
  3. Advances in nucleic acid-based cancer vaccines.Journal of biomedical science · 2025
    Review
  4. Article
  5. Viral vector-based therapeutic HPV vaccines.Clinical and experimental medicine · 2024
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Tumor microenvironment and immunotherapy of oral cancer.European journal of medical research · 2022
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Ssu-Hsueh Tseng *Department of Pathology, Johns Hopkins University, CRB II, 1550 Orleans St, Baltimore, MD, 21287, USA.
Li Liu *Department of Pathology, Johns Hopkins University, CRB II, 1550 Orleans St, Baltimore, MD, 21287, USA.
Shiwen PengDepartment of Pathology, Johns Hopkins University, CRB II, 1550 Orleans St, Baltimore, MD, 21287, USA.
Jinhwi KimDepartment of Obstetrics and Gynecology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 271, Cheonbo-Ro, Uijeongbu, Gyeonggi-do, 11765, Republic of Korea.
Louise FerrallDepartment of Pathology, Johns Hopkins University, CRB II, 1550 Orleans St, Baltimore, MD, 21287, USA.
Chien-Fu Hung *Department of Pathology, Johns Hopkins University, CRB II, 1550 Orleans St, Baltimore, MD, 21287, USA. chung2@jhmi.edu.
T -C Wu *Department of Pathology, Johns Hopkins University, CRB II, 1550 Orleans St, Baltimore, MD, 21287, USA. wutc@jhmi.edu.ORCID http://orcid.org/0000-0003-1623-4584
Johns Hopkins University · USThe Catholic University of Korea Uijeongbu St. Mary's Hospital · KR

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZYY-CHOOU WU · 2003 to 2026
$53.5M
Mouse modeling of HPV infectionR01CA233486 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU, RODEN, RICHARD BRUCE · 2019 to 2023
$3.0M
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer ImmunotherapyR01CA237067 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2019 to 2023
$2.9M
Development and Characterization of Immunotherapies for HPV-Associated MalignanciesR50CA251953 · NCI · JOHNS HOPKINS UNIVERSITY · PI PENG, SHIWEN · 2020 to 2024
$490k
NCI NIH HHS P50 CA098252NCI NIH HHS P50CA098252NCI NIH HHS R01 CA233486NCI NIH HHS R01 CA237067NCI NIH HHS R01CA237067NCI NIH HHS R50 CA251953
6 · The paper itself

Abstract

backgroundHuman Papillomavirus type 16 (HPV16) has been associated with a subset of head and neck cancers. Two HPV encoded oncogenic proteins, E6 and E7, are important for the malignant progression of HPV-associated cancers. A spontaneous HPV16 E6/E7-expressing oral tumor model in human HLA-A2 (AAD) transgenic mice will be important for the development of therapeutic HPV vaccines for the control of HPV-associated head and neck cancers.

methodsIn the current studies, we characterized the HLA-A2 restricted HPV16 E7-specific CD8 + T cell mediated immune responses in the HLA-A2 (AAD) transgenic mice using a therapeutic naked DNA vaccine encoding calreticulin (CRT) linked to a mutated E7(N53S). We also employed oncogenic DNA plasmids that encoded HPV16E6/E7/Luc, NRas

resultsWe found that CRT/E7(N53S) DNA vaccine primarily generated human HPV16 E7 peptide (aa11-20) specific CD8 + T cells, as compared to the wild-type CRT/E7 vaccine, which primarily generated murine H-2D

conclusionsTaken together, the data indicated that the combination of HPV16 E6/E7-expressing DNA, NRas

Indexed as

AnimalsHLA-A2 AntigenMiceMice, TransgenicMouth NeoplasmsOncogene Proteins, ViralPapillomavirus InfectionsPapillomavirus VaccinesRepressor ProteinsE6 protein, Human papillomavirus type 16HLA-A2 AntigenOncogene Proteins, ViralPapillomavirus VaccinesRepressor ProteinsDNA vaccineHLA-A2HPVHPV16Preclinical modelTransgenic mice

Identifiers

PMID34517865
PMCPMC8436567
OpenAlexW3200812574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.